Symbols / SGMT Stock $5.86 -0.17% Sagimet Biosciences Inc.
SGMT (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Ratings
Current target
$5.86
Low
$8.00
High
$35.00
Mean
$25.78
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-11 | reit | HC Wainwright & Co. | Buy → Buy | $29 |
| 2026-02-03 | init | Guggenheim | — → Buy | $27 |
| 2026-02-03 | reit | HC Wainwright & Co. | Buy → Buy | $29 |
| 2026-01-28 | init | Barclays | — → Equal-Weight | $8 |
| 2025-11-14 | main | Citizens | Market Outperform → Market Outperform | $35 |
| 2025-10-22 | init | Clear Street | — → Buy | $29 |
| 2025-10-02 | main | Canaccord Genuity | Buy → Buy | $28 |
| 2025-08-11 | init | Wedbush | — → Outperform | $28 |
| 2025-07-24 | init | Canaccord Genuity | — → Buy | $28 |
| 2025-06-06 | main | Jones Trading | Buy → Buy | $27 |
| 2025-03-13 | reit | HC Wainwright & Co. | Buy → Buy | $32 |
| 2025-03-11 | reit | HC Wainwright & Co. | Buy → Buy | $32 |
| 2025-01-27 | init | Jones Trading | — → Buy | $42 |
| 2024-12-06 | init | Oppenheimer | — → Outperform | $30 |
| 2024-11-15 | reit | HC Wainwright & Co. | Buy → Buy | $32 |
| 2024-11-12 | init | UBS | — → Buy | $12 |
| 2024-10-31 | reit | HC Wainwright & Co. | Buy → Buy | $32 |
| 2024-10-02 | reit | HC Wainwright & Co. | Buy → Buy | $32 |
| 2024-08-15 | main | JMP Securities | Market Outperform → Market Outperform | $32 |
| 2024-08-15 | reit | HC Wainwright & Co. | Buy → Buy | $32 |
- Sagimet turns to two-decade drug veteran after its medical chief retires - Stock Titan Mon, 20 Apr 2026 11
- Sagimet Biosciences Inc. (SGMT) Presents at Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium - Slideshow (NASDAQ:SGMT) 2026-04-20 - Seeking Alpha Mon, 20 Apr 2026 23
- Why Sagimet (SGMT) Stock Is Interesting (Breakdown Watch) 2026-04-20 - Expert Market Insights - Cổng thông tin điện tử tỉnh Tây Ninh Mon, 20 Apr 2026 16
- Analysts Remain Optimistic in Sagimet Biosciences (SGMT)’s Outlook Following Q4 and Full-Year 2025 Results - Yahoo Finance Wed, 25 Mar 2026 07
- $SGMT stock is up 12% today. Here's what we see in our data. - Quiver Quantitative Fri, 09 Jan 2026 08
- Don't Ignore The Insider Selling In Sagimet Biosciences - simplywall.st Sun, 15 Feb 2026 08
- Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Mon, 06 Apr 2026 11
- Sagimet Biosciences (SGMT) CMO retires as company appoints successor - Stock Titan ue, 21 Apr 2026 10
- A Look At Sagimet Biosciences (SGMT) Valuation After Denifanstat’s Phase 3 Acne Trial Success - Yahoo Finance Wed, 04 Feb 2026 08
- Sagimet (SGMT) Stock: Breakout or Breakdown (+4.52%) 2026-04-18 - Mid Cap Momentum - Cổng thông tin điện tử Tỉnh Sơn La Sat, 18 Apr 2026 07
- Here's Why We're Not Too Worried About Sagimet Biosciences' (NASDAQ:SGMT) Cash Burn Situation - simplywall.st Sat, 18 Apr 2026 13
- Sagimet Biosciences (SGMT) details 2026 virtual meeting, board elections and KPMG audit vote - Stock Titan ue, 21 Apr 2026 20
- All You Need to Know About Sagimet Biosciences Inc. (SGMT) Rating Upgrade to Strong Buy - Yahoo Finance Wed, 15 Oct 2025 07
- $SGMT stock is up 10% today. Here's what we see in our data. - Quiver Quantitative Fri, 24 Oct 2025 07
- Sagimet spotlights biomarker shift in fatty liver drug study - Stock Titan Mon, 06 Apr 2026 07
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
-100.00%
|
2.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
-100.00%
|
2.00
|
0.00
|
| Operating Expense |
|
56.89
+4.47%
|
54.45
+66.32%
|
32.74
+5.43%
|
31.05
|
| Research And Development |
|
39.05
+1.59%
|
38.44
+94.39%
|
19.78
-20.63%
|
24.92
|
| Selling General And Administration |
|
17.84
+11.40%
|
16.01
+23.51%
|
12.96
+111.26%
|
6.14
|
| General And Administrative Expense |
|
17.84
+11.40%
|
16.01
+23.51%
|
12.96
+111.26%
|
6.14
|
| Other Gand A |
|
17.84
+11.40%
|
16.01
+23.51%
|
12.96
+111.26%
|
6.14
|
| Total Expenses |
|
56.89
+4.47%
|
54.45
+66.32%
|
32.74
+5.43%
|
31.05
|
| Operating Income |
|
-56.89
-4.47%
|
-54.45
-77.14%
|
-30.74
+1.01%
|
-31.05
|
| Total Operating Income As Reported |
|
-56.89
-4.47%
|
-54.45
-77.14%
|
-30.74
+1.01%
|
-31.05
|
| EBITDA |
|
-56.89
-4.47%
|
-54.45
-77.14%
|
-30.74
+1.01%
|
-31.05
|
| Normalized EBITDA |
|
-56.89
-4.47%
|
-54.45
-77.12%
|
-30.74
+1.01%
|
-31.06
|
| EBIT |
|
-56.89
-4.47%
|
-54.45
-77.14%
|
-30.74
+1.01%
|
-31.05
|
| Total Unusual Items |
|
—
|
—
|
0.00
+33.33%
|
0.00
|
| Total Unusual Items Excluding Goodwill |
|
—
|
—
|
0.00
+33.33%
|
0.00
|
| Net Income |
|
-51.04
-12.01%
|
-45.57
-63.46%
|
-27.88
+8.60%
|
-30.50
|
| Pretax Income |
|
-51.04
-12.01%
|
-45.57
-63.46%
|
-27.88
+8.60%
|
-30.50
|
| Net Non Operating Interest Income Expense |
|
5.85
-34.16%
|
8.89
+210.73%
|
2.86
+417.18%
|
0.55
|
| Net Interest Income |
|
5.85
-34.16%
|
8.89
+210.73%
|
2.86
+417.18%
|
0.55
|
| Interest Income Non Operating |
|
5.85
-34.16%
|
8.89
+210.73%
|
2.86
+417.18%
|
0.55
|
| Interest Income |
|
5.85
-34.16%
|
8.89
+210.73%
|
2.86
+417.18%
|
0.55
|
| Other Income Expense |
|
—
|
—
|
0.00
+33.33%
|
0.00
|
| Other Non Operating Income Expenses |
|
—
|
—
|
—
|
0.00
|
| Gain On Sale Of Security |
|
—
|
—
|
0.00
+33.33%
|
0.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-51.04
-12.01%
|
-45.57
-63.46%
|
-27.88
+8.60%
|
-30.50
|
| Net Income From Continuing Operation Net Minority Interest |
|
-51.04
-12.01%
|
-45.57
-63.46%
|
-27.88
+8.60%
|
-30.50
|
| Net Income From Continuing And Discontinued Operation |
|
-51.04
-12.01%
|
-45.57
-63.46%
|
-27.88
+8.60%
|
-30.50
|
| Net Income Continuous Operations |
|
-51.04
-12.01%
|
-45.57
-63.46%
|
-27.88
+8.60%
|
-30.50
|
| Normalized Income |
|
-51.04
-12.01%
|
-45.57
-63.44%
|
-27.88
+8.60%
|
-30.50
|
| Net Income Common Stockholders |
|
-51.04
-12.01%
|
-45.57
-63.46%
|
-27.88
+8.60%
|
-30.50
|
| Diluted EPS |
|
—
|
-1.45
+45.49%
|
-2.66
-93.39%
|
-1.38
|
| Basic EPS |
|
—
|
-1.45
+45.49%
|
-2.66
-93.39%
|
-1.38
|
| Basic Average Shares |
|
—
|
31.35
+199.71%
|
10.46
-52.83%
|
22.17
|
| Diluted Average Shares |
|
—
|
31.35
+199.71%
|
10.46
-52.83%
|
22.17
|
| Diluted NI Availto Com Stockholders |
|
-51.04
-12.01%
|
-45.57
-63.46%
|
-27.88
+8.60%
|
-30.50
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
116.48
-27.32%
|
160.26
+65.70%
|
96.72
+192.81%
|
33.03
|
| Current Assets |
|
116.40
-23.81%
|
152.77
+58.08%
|
96.65
+194.72%
|
32.79
|
| Cash Cash Equivalents And Short Term Investments |
|
113.12
-25.21%
|
151.25
+59.38%
|
94.90
+193.39%
|
32.34
|
| Cash And Cash Equivalents |
|
35.02
-53.82%
|
75.84
+0.93%
|
75.14
+47456.33%
|
0.16
|
| Other Short Term Investments |
|
78.10
+3.57%
|
75.41
+281.67%
|
19.76
-38.61%
|
32.19
|
| Prepaid Assets |
|
2.80
+163.81%
|
1.06
-21.52%
|
1.35
+227.36%
|
0.41
|
| Current Deferred Assets |
|
0.28
-7.84%
|
0.31
-5.26%
|
0.32
|
0.00
|
| Other Current Assets |
|
0.20
+26.75%
|
0.16
+112.16%
|
0.07
+117.65%
|
0.03
|
| Total Non Current Assets |
|
0.08
-98.96%
|
7.49
+10153.42%
|
0.07
-69.46%
|
0.24
|
| Net PPE |
|
0.08
+1.30%
|
0.08
+5.48%
|
0.07
-65.57%
|
0.21
|
| Gross PPE |
|
0.08
+1.30%
|
0.08
+5.48%
|
0.07
-65.57%
|
0.21
|
| Other Properties |
|
0.08
+1.30%
|
0.08
+5.48%
|
0.07
-65.57%
|
0.21
|
| Investments And Advances |
|
0.00
-100.00%
|
7.41
|
0.00
|
—
|
| Non Current Prepaid Assets |
|
—
|
—
|
0.00
-100.00%
|
0.03
|
| Total Liabilities Net Minority Interest |
|
5.10
+14.53%
|
4.45
-21.22%
|
5.65
-97.43%
|
219.98
|
| Current Liabilities |
|
5.10
+14.53%
|
4.45
-21.22%
|
5.65
+7.10%
|
5.28
|
| Payables And Accrued Expenses |
|
5.00
+14.30%
|
4.37
-18.39%
|
5.36
+5.25%
|
5.09
|
| Payables |
|
1.31
-8.14%
|
1.43
+666.13%
|
0.19
-83.47%
|
1.12
|
| Accounts Payable |
|
1.31
-8.14%
|
1.43
+666.13%
|
0.19
-83.47%
|
1.12
|
| Current Accrued Expenses |
|
3.69
+25.15%
|
2.95
-43.02%
|
5.17
+30.42%
|
3.96
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
—
|
—
|
1.10
+73.74%
|
0.64
|
| Current Debt And Capital Lease Obligation |
|
0.08
+0.00%
|
0.08
+20.00%
|
0.07
-51.13%
|
0.13
|
| Current Capital Lease Obligation |
|
0.08
+0.00%
|
0.08
+20.00%
|
0.07
-51.13%
|
0.13
|
| Other Current Liabilities |
|
0.03
+440.00%
|
0.01
-97.85%
|
0.23
+308.77%
|
0.06
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
|
0.00
|
0.00
-100.00%
|
214.70
|
| Long Term Debt And Capital Lease Obligation |
|
—
|
—
|
0.00
-100.00%
|
0.08
|
| Long Term Capital Lease Obligation |
|
—
|
—
|
0.00
-100.00%
|
0.08
|
| Preferred Securities Outside Stock Equity |
|
—
|
—
|
0.00
-100.00%
|
214.62
|
| Stockholders Equity |
|
111.38
-28.51%
|
155.81
+71.09%
|
91.06
+148.71%
|
-186.95
|
| Common Stock Equity |
|
111.38
-28.51%
|
155.81
+71.09%
|
91.06
+148.71%
|
-186.95
|
| Capital Stock |
|
0.00
+0.00%
|
0.00
+50.00%
|
0.00
+100.00%
|
0.00
|
| Common Stock |
|
0.00
+0.00%
|
0.00
+50.00%
|
0.00
+100.00%
|
0.00
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
32.52
+1.01%
|
32.20
+40.62%
|
22.90
+3.26%
|
22.17
|
| Ordinary Shares Number |
|
32.52
+1.01%
|
32.20
+40.62%
|
22.90
+3.26%
|
22.17
|
| Additional Paid In Capital |
|
457.61
+1.49%
|
450.88
+32.31%
|
340.78
+873.62%
|
35.00
|
| Retained Earnings |
|
-346.35
-17.28%
|
-295.31
-18.25%
|
-249.74
-12.56%
|
-221.87
|
| Gains Losses Not Affecting Retained Earnings |
|
0.12
-47.83%
|
0.23
+666.67%
|
0.03
+135.71%
|
-0.08
|
| Other Equity Adjustments |
|
0.12
-47.83%
|
0.23
+666.67%
|
0.03
+135.71%
|
-0.08
|
| Total Equity Gross Minority Interest |
|
111.38
-28.51%
|
155.81
+71.09%
|
91.06
+148.71%
|
-186.95
|
| Total Capitalization |
|
111.38
-28.51%
|
155.81
+71.09%
|
91.06
+148.71%
|
-186.95
|
| Working Capital |
|
111.30
-24.96%
|
148.32
+63.00%
|
90.99
+230.72%
|
27.51
|
| Invested Capital |
|
111.38
-28.51%
|
155.81
+71.09%
|
91.06
+148.71%
|
-186.95
|
| Total Debt |
|
0.08
+0.00%
|
0.08
+20.00%
|
0.07
-69.19%
|
0.21
|
| Capital Lease Obligations |
|
0.08
+0.00%
|
0.08
+20.00%
|
0.07
-69.19%
|
0.21
|
| Net Tangible Assets |
|
111.38
-28.51%
|
155.81
+71.09%
|
91.06
+148.71%
|
-186.95
|
| Tangible Book Value |
|
111.38
-28.51%
|
155.81
+71.09%
|
91.06
+148.71%
|
-186.95
|
| Available For Sale Securities |
|
—
|
7.41
|
—
|
—
|
| Derivative Product Liabilities |
|
—
|
—
|
0.00
-100.00%
|
0.00
|
| Investmentin Financial Assets |
|
0.00
-100.00%
|
7.41
|
0.00
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-45.65
-7.58%
|
-42.44
-78.55%
|
-23.77
+2.96%
|
-24.49
|
| Cash Flow From Continuing Operating Activities |
|
-45.65
-7.58%
|
-42.44
-78.55%
|
-23.77
+2.96%
|
-24.49
|
| Net Income From Continuing Operations |
|
-51.04
-12.01%
|
-45.57
-63.46%
|
-27.88
+8.60%
|
-30.50
|
| Other Non Cash Items |
|
0.15
+4.14%
|
0.14
+4.32%
|
0.14
+6.92%
|
0.13
|
| Stock Based Compensation |
|
6.45
+21.96%
|
5.29
+5.97%
|
4.99
+165.43%
|
1.88
|
| Asset Impairment Charge |
|
0.23
|
0.00
|
—
|
—
|
| Operating Gains Losses |
|
—
|
—
|
-0.00
-33.33%
|
-0.00
|
| Gain Loss On Investment Securities |
|
—
|
—
|
-0.00
-33.33%
|
-0.00
|
| Unrealized Gain Loss On Investment Securities |
|
—
|
—
|
—
|
0.00
|
| Change In Working Capital |
|
-1.05
-0.48%
|
-1.05
-7.16%
|
-0.98
-123.21%
|
4.21
|
| Change In Prepaid Assets |
|
-1.83
-36500.00%
|
-0.01
+99.47%
|
-0.95
-166.30%
|
1.44
|
| Change In Payables And Accrued Expense |
|
0.93
+202.43%
|
-0.91
-855.83%
|
0.12
-95.88%
|
2.92
|
| Change In Other Current Liabilities |
|
-0.15
-11.76%
|
-0.14
+6.85%
|
-0.15
-6.57%
|
-0.14
|
| Investing Cash Flow |
|
4.56
+107.39%
|
-61.68
-590.33%
|
12.58
+139.30%
|
-32.01
|
| Cash Flow From Continuing Investing Activities |
|
4.56
+107.39%
|
-61.68
-590.33%
|
12.58
+139.30%
|
-32.01
|
| Net Investment Purchase And Sale |
|
4.56
+107.39%
|
-61.68
-590.33%
|
12.58
+139.30%
|
-32.01
|
| Purchase Of Investment |
|
-106.86
+1.13%
|
-108.09
-450.90%
|
-19.62
+52.66%
|
-41.45
|
| Sale Of Investment |
|
111.42
+140.11%
|
46.40
+44.11%
|
32.20
+241.25%
|
9.44
|
| Financing Cash Flow |
|
0.28
-99.74%
|
104.82
+21.65%
|
86.17
+118136.99%
|
-0.07
|
| Cash Flow From Continuing Financing Activities |
|
0.28
-99.74%
|
104.82
+21.65%
|
86.17
+118136.99%
|
-0.07
|
| Net Common Stock Issuance |
|
0.00
-100.00%
|
105.75
+17.92%
|
89.68
|
0.00
|
| Proceeds From Stock Option Exercised |
|
0.28
+141.23%
|
0.11
+1800.00%
|
0.01
-50.00%
|
0.01
|
| Net Other Financing Charges |
|
—
|
-1.04
+70.30%
|
-3.52
-4038.82%
|
-0.09
|
| Changes In Cash |
|
-40.82
-5922.97%
|
0.70
-99.07%
|
74.98
+232.54%
|
-56.57
|
| Beginning Cash Position |
|
75.84
+0.93%
|
75.14
+47456.33%
|
0.16
-99.72%
|
56.73
|
| End Cash Position |
|
35.02
-53.82%
|
75.84
+0.93%
|
75.14
+47456.33%
|
0.16
|
| Free Cash Flow |
|
-45.65
-7.58%
|
-42.44
-78.55%
|
-23.77
+2.96%
|
-24.49
|
| Amortization Of Securities |
|
-0.39
+68.95%
|
-1.25
-3286.49%
|
-0.04
+82.55%
|
-0.21
|
| Common Stock Issuance |
|
0.00
-100.00%
|
105.75
+17.92%
|
89.68
|
0.00
|
| Issuance Of Capital Stock |
|
0.00
-100.00%
|
105.75
+17.92%
|
89.68
|
0.00
|
| Net Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
| Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-21 View
- 8-K2026-03-11 View
- 10-K2026-03-11 View
- 42026-02-20 View
- 42026-02-20 View
- 42026-02-20 View
- 42026-02-20 View
- 42026-02-12 View
- 42026-02-12 View
- 42026-02-12 View
- 42026-02-12 View
- 8-K2026-02-02 View
- 8-K2025-12-18 View
- 8-K2025-12-17 View
- 42025-11-21 View
- 8-K2025-11-13 View
- 10-Q2025-11-13 View
- 42025-11-06 View
- 8-K2025-10-23 View
- 8-K2025-08-22 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|